Close Menu

Becton Dickinson

BD Life Sciences revenues rose 5 percent to $982 million, driven by strong growth in diagnostics products, which were up 10 percent. 

The firms expect that the acquisition will yield a medical technology company positioned to improve the process of care and the treatment of disease.

BD said that the system provides blood banks and clinical labs with an automated flow cytometer that quantifies the presence of residual white blood cells.

The semifinalists will receive $50,000 each to develop prototypes of their concepts for submission in the second phase of the challenge.

New minimum performance requirements may reduce the number of misdiagnosed influenza infections, according to the FDA. 

The firm said it continues to see strong growth in BD Max, and has plans to launch an extended enteric bacterial panel in the US later this year.

The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.

The firm said it is on track for solid future growth based on the expectation for new product approvals and continued strength in the CareFusion product portfolio. 

The assay runs on the BD Max System, which combines automated real-time PCR extraction, amplification, and detection on a single platform.

The committee questioned stakeholders about the impact of FDA oversight of LDTs, and whether there was any consensus about how to move forward on a divisive topic.